Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Black Diamond Therapeutics Announces Oral Presentation of
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) is presenting multiple updates on its drug silevertinib at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations include oral results from a Phase 2 study of silevertinib in frontline non-small cell lung cancer (NSCLC) patients with non-classical EGFR mutations, as well as poster presentations for previously treated NSCLC patients and a trial-in-progress for glioblastoma (GBM) patients. Silevertinib is an oral, brain-penetrant fourth-generation tyrosine kinase inhibitor designed to target various EGFR mutations in cancer.